Scientific Context & Problem Investigated
Metabolic dysfunction and insulin resistance represent major global health challenges. High-glycemic diets and oxidative stress drive excessive blood glucose variability, which over time impairs microvascular capillary networks and vital organs.
To evaluate the impact of daily administration of Betterdays Triple Bioactive Peptides over 90 days on fasting blood glucose (FBG) maintenance, glycated hemoglobin (HbA1c) profiles, postprandial glucose tolerance (PPG), as well as safety and tolerability profiles in adult human subjects.
Protocol & Study Methodology
A. Targeted Biological Mechanism
Targeted short-chain Bitter Melon peptides act as natural insulin mimetics by triggering GLUT4 glucose transporter translocation in muscle tissue. Walnut and Soy oligopeptides provide vascular anti-oxidative support to maintain endothelial elasticity.
B. Evaluation Protocol & Phase Timeline
Screening & Baseline Phase
Initial blood work (HbA1c, FBG, PPG), inclusion screening, and baseline lipid profile mapping.
Initial Intervention Phase
Administration of 1 sachet Betterdays daily 30 minutes before primary meal. Weekly glucose tracking.
Midterm Evaluation Phase
Mid-study laboratory testing for FBG dynamics and cellular tolerance evaluation.
Final Endpoint Evaluation
Comprehensive final endpoint lab testing (HbA1c, FBG, PPG, liver & renal panels).
| Assessment Metric | Baseline (Day 0) | Week 4 (Day 30) | Week 8 (Day 60) | Week 12 (Day 90) |
|---|---|---|---|---|
| Gula Darah Puasa (FBG) | ✔ | ✔ | ✔ | ✔ |
| Profil HbA1c Lab | ✔ | - | ✔ | ✔ |
| 2-Hour Postprandial (PPG) | ✔ | ✔ | - | ✔ |
| Panel Keamanan Hepar & Ginjal | ✔ | - | - | ✔ |
C. Eligibility Criteria & Demographics
- — Male & female participants aged 25–65 years
- — Baseline Fasting Blood Glucose (FBG) between 100–186 mg/dL
- — Baseline HbA1c level between 6.8% – 9.2%
- — Willing to consume 1 sachet daily and record daily compliance logs for 90 days
- — Signed voluntary written informed consent
- — Use of high-dose exogenous insulin therapy
- — History of severe hepatic or renal dysfunction (eGFR < 30 mL/min)
- — Pregnant, lactating, or planning pregnancy
- — Known allergy to soy or walnut proteins
- — Participation in other interventional clinical trials within the past 30 days
D. Product Specifications & Dosing
Efficacy Lab Results & Glycemic Biomarkers
01 · Primary Endpoints
| Lab Biomarker | Baseline (Day 0) | Day 30 | Day 60 | Day 90 | Net Change | Significance |
|---|---|---|---|---|---|---|
| Mean HbA1c (%) | 8.15% | 7.60% | 7.05% | 6.55% | -1.6% | p < 0.001 |
| Fasting Glucose (mg/dL) | 154.2 mg/dL | 141.0 mg/dL | 128.5 mg/dL | 115.2 mg/dL | -39 mg/dL | p < 0.001 |
02 · Secondary Outcomes & Observations
From 204 mg/dL to 152 mg/dL at Day 90
78/80 participants completed full 90-day protocol
Increased vitality perception and reduction in post-meal drowsiness
Medical Safety Observations & Organ Markers
Administration of the Betterdays formulation over 90 days was observed to be safe and well-tolerated. Zero Serious Adverse Events (SAEs) were reported. Liver function markers (ALT/AST) and kidney function markers (Urea/Creatinine) remained within normal physiological reference ranges throughout the trial period.
Biological Mechanism Interpretation
The findings of this clinical trial confirm the hypothesis that plant-derived bioactive peptides (Bitter Melon, Walnut, Soy) act synergistically via rapid intestinal absorption pathways. Specific bitter melon peptides exhibit insulin-mimetic characteristics by activating GLUT4 glucose transporters, while walnut and soy oligopeptides attenuate vascular inflammation and lipid oxidation. The observed reductions of 1.6% in HbA1c and 39 mg/dL in FBG underscore the significant potential of targeted bioactive nutrition as a standalone lifestyle support strategy.
Research Documents & Frequently Asked Questions
FREQUENTLY ASKED CLINICAL QUESTIONS
Over 90 days of clinical evaluation, zero Serious Adverse Events (SAEs) were reported. The recommended 1 daily sachet dose proved well-tolerated by participants.
Based on laboratory data, fasting blood glucose drops were observed starting at Week 4 (Day 30), reaching optimal mean HbA1c reduction (-1.6%) at Week 12 (Day 90).
Participants taking routine prescribed therapies were advised to maintain a 1–2 hour interval between intake and consult their monitoring physician.
Participants were instructed to resume 1 sachet on the following day without doubling the dose.
